性感染症診断薬市場：疾患タイプ、診断方法、デバイスタイプ、エンドユーザー別-世界予測2024-2030年

性感染症診断薬市場規模は、2023年に1,065億3,000万米ドルと推定され、2024年には1,125億6,000万米ドルに達し、CAGR 5.97％で2030年には1,599億7,000万米ドルに達すると予測されています。

性感染症診断薬は、性的接触を通じて感染する感染症を特定するために使用される医療検査、身体検査、処置の範囲を指します。これらの診断法は性感染症の早期発見、治療、予防に不可欠であり、公衆衛生の取り組みと個人の幸福を支えています。性感染症（STD）診断の手法はさまざまで、核酸増幅検査、培養、酵素免疫測定法（EIA）などの検査室ベースの検査や、迅速な結果が得られるポイントオブケア検査などがあります。世界の性病有病率の上昇は、診断薬の成長に大きく寄与しています。この増加は、性行動の変化、性の健康に関する教育と意識の欠如、特定の地域における不十分なスクリーニングプログラムに起因しています。そのため、効果的な診断ソリューションの必要性が強調され、STD診断薬に対する需要の高まりを促しています。しかし、STDに関連する社会的スティグマは、STD診断プロバイダーにとって依然として大きな課題です。公開会社は公衆衛生の一環としてSTDの予防と管理にますます力を入れるようになっています。さらに、分子診断、ポリメラーゼ連鎖反応（PCR）検査、免疫測定法などの医療診断技術の急速な進歩により、STD検査の精度、効率、スピードが大幅に向上しています。このような技術の進歩により、性病の早期発見と治療が容易になり、性病診断の成長をさらに促進しています。

疾患の種類次世代シーケンサーとCRISPRベースの診断法の進歩により、多様なSTDに対応可能

性感染症（STD）診断の研究には、性の健康に影響を及ぼす幅広い疾患が含まれます。その中には、おりものや不快感などの症状を引き起こす膣内細菌の不均衡に起因する細菌性膣炎が含まれます。カンジダ性膣炎またはイースト菌感染症は、カンジダ菌の過剰増殖から生じ、かゆみや炎症を引き起こします。一方、クラミジア・トラコマティスや淋菌など、性的接触によって感染する感染症は、すぐに症状が現れないことが多く、放置しておくと深刻な生殖器の問題に発展する可能性があります。性器疣贅は、特定のHPV株によるもので、性器領域に疣贅として現れます。HIV/AIDSは免疫系を著しく低下させ、生命を脅かす感染症を引き起こします。マイコプラズマ・ジェニタリウムという細菌は、あまり知られていないが、尿道炎や骨盤内炎症性疾患などの症状に関連しています。梅毒は細菌感染症で、段階を経て進行し、最初はただれや皮疹を引き起こし、治療なしでは内臓に深刻なダメージを与えます。最後に、トリコモナス膣炎は、トリコモナス原虫によって引き起こされ、かゆみとおりものが特徴であるが、通常は抗生物質で治癒可能です。

エンドユーザー複雑なSTD症例に対応するため、臨床および病院環境におけるSTD診断の採用が増加しています。

性感染症（STD）診断には様々なヘルスケアや調査の場があり、それぞれがSTDの検出、分析、管理において重要な役割を果たしています。診療所はSTD診断の最前線であることが多く、一般の人々に直接利用しやすい検査サービスを提供しています。診断検査機関は正確な結果を得るために高度な技術を駆使し、検体の分析を専門としています。病院は、特に入院治療を必要とする重症例や複雑な症例において、STD診断を含む包括的な治療を提供しています。公衆衛生機関は、診断データを公衆衛生戦略や介入策に役立てることで、STDの監視、予防、管理に不可欠な存在です。さらに研究機関は、新しい診断方法の開発やSTDの疫学的理解において重要な役割を担っており、公衆衛生対策や臨床実践を推進するために必要な科学的基盤の構築に貢献しています。

地域別の洞察

南北アメリカでは、性感染症（STD）の蔓延が拡大しており、健康意識とヘルスケア支出の増加も相まって、診断ソリューションの需要を後押ししています。高度なヘルスケアインフラと最先端診断技術の高い普及率が、消費者の高度な期待に寄与しています。最近の取り組みとしては、恵まれない人々のSTD診断を強化するための公衆衛生プログラムへの多額の投資が挙げられます。同時にEMEAは、革新的な診断ソリューションの研究開発および流通を促進する政府および非政府機関のイニシアティブに支えられ、STD診断に対する積極的なアプローチを示しています。費用対効果と包括的なカバー範囲に重点が置かれ、都市部や農村部での利用しやすさを目指しています。近年、アジア太平洋地域では、教育、啓発、性病にまつわる偏見の解消を目的とした取り組みが徐々に進展し、診断サービスへの需要が徐々に高まっています。さらに、アジア太平洋地域は、性病に対する意識の高まり、性病の有病率の上昇、およびこれらの感染症の抑制を目的とした政府の取り組みによって、性病診断市場の成長に熱心です。中国、インド、日本、オーストラリアなど、国によって多様な人口と多様な医療インフラが存在するため、市場力学は高度な技術導入と費用対効果の高い診断ソリューションに対する需要の高まりが混在していることが特徴となっています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは性感染症診断薬市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、性感染症診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.性感染症診断薬市場の市場規模および予測は？

2.性感染症診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.性感染症診断薬市場の技術動向と規制枠組みは？

4.性感染症診断薬市場における主要ベンダーの市場シェアは？

5.性感染症診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で性病の蔓延が拡大しており、効果的な診断ソリューションの必要性が高まっている
    • 性感染症に関連する偏見を減らすために、世界中で検査の実施を増やす
  • 抑制要因
    • 性感染症に関する十分な認識と教育の欠如
  • 機会
    • 性感染症の啓発と予防のための資金と公衆衛生キャンペーンの増強
    • 次世代シーケンシングとCRISPRベースの診断におけるイノベーション
  • 課題
    • 薬剤の承認と未治療の感染症から生じる合併症に関する厳格な政府規制
• 市場セグメンテーション分析
  • 疾患タイプ：次世代シーケンシングとCRISPRベースの診断の進歩により、さまざまなSTDに対応
  • エンドユーザー：複雑な性感染症の症例に対応するために、臨床および病院の現場で性感染症診断の採用が増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 性感染症診断薬市場：疾患タイプ別

• 細菌性膣炎
• カンジダ膣炎
• クラミジア・トラコマティス/淋菌
• 性器イボ
• B型肝炎
• HIV/エイズ
• マイコプラズマ・ジェニタリウム
• 梅毒
• トリコモナス症

第7章 性感染症診断薬市場診断方法別

• 抗原検出
• 分子診断
• 血清学的検査

第8章 性感染症診断薬市場デバイスタイプ別

• 実験装置
• ポイントオブケアデバイス

第9章 性感染症診断薬市場：エンドユーザー別

• クリニック
• 診断検査室
• 病院
• 公衆衛生機関
• 調査機関

第10章 南北アメリカの性感染症診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の性感染症診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの性感染症診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 英国のスタートアップ企業が性感染症検査機能付きタンポンを発売
  • BioPerfectusが性感染症診断ソリューション用の新しいPCRキットを発売
  • マイラボ、性感染症の迅速検査を開始
• 戦略分析と提言

第14章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 81. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 82. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 83. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 84. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 93. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 94. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 95. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 96. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 105. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 106. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 107. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 108. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 109. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 110. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 111. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 112. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 113. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 114. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 115. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 116. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 117. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 118. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 119. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 120. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 129. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 130. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 131. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 132. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 143. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 144. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 145. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 146. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 158. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 160. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 167. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 168. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 169. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 170. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 171. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 172. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 173. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 174. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 175. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 176. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 177. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 178. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 179. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 180. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 181. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 182. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 183. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 184. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 185. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 186. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 187. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 188. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 189. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 190. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 191. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 192. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 193. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 194. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 195. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 196. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 203. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 204. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 205. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 206. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 207. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 208. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 215. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 216. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 217. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 218. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 219. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 220. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 227. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 228. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 229. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 230. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 231. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 232. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 239. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 240. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 241. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 242. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 243. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 244. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 251. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 252. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 253. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 254. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 255. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 256. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 263. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
• TABLE 264. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
• TABLE 265. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
• TABLE 266. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
• TABLE 267. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
• TABLE 268. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
• TABLE 275. TAIWAN SEXUALLY

[180 Pages Report] The Sexually Transmitted Disease Diagnostics Market size was estimated at USD 106.53 billion in 2023 and expected to reach USD 112.56 billion in 2024, at a CAGR 5.97% to reach USD 159.97 billion by 2030.

Sexually transmitted disease diagnostics refers to the range of medical tests, physical examinations, and procedures used to identify infections transmitted through sexual contact. These diagnostics are crucial for the early detection, treatment, and prevention of sexually transmitted diseases, supporting public health efforts and individual well-being. The methodologies for Sexually transmitted disease (STD) diagnostics vary, including laboratory-based tests such as nucleic acid amplification tests, cultures, enzyme immunoassays (EIAs), and point-of-care tests that offer rapid results. The rising prevalence of STDs worldwide is a major contributor to the growth of diagnostics. This increase is attributed to changing sexual behaviors, lack of education and awareness regarding sexual health, and insufficient screening programs in certain regions. The need for effective diagnostic solutions is thus highlighted, prompting an uptick in demand for STD diagnostics. However, the social stigma associated with STDs remains a significant challenge for STD diagnostic providers. Companies are increasingly focusing on STD prevention and control as part of their public health initiatives. Moreover, the rapid progress in medical diagnostic technologies, including molecular diagnostics, Polymerase Chain Reaction (PCR) testing, and immunoassays, has significantly enhanced the accuracy, efficiency, and speed of STD testing. These technological advancements facilitate the early detection and treatment of STDs, further driving the growth of STD diagnostics.

Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs

The study of sexually transmitted disease (STD) diagnostics encompasses a broad range of conditions affecting sexual health. These include bacterial vaginosis, a condition stemming from an imbalance of bacteria in the vagina, which leads to symptoms such as discharge and discomfort. Candidal vaginitis or yeast infection arises from an overgrowth of Candida fungi, causing itching and irritation. On the other hand, infections such as Chlamydia trachomatis and Neisseria Gonorrhoeae, transmitted through sexual contact, often show no immediate symptoms and can lead to severe reproductive issues that are left unaddressed. Genital Warts are the result of certain HPV strains, presenting as warts on the genital area. HIV/AIDS severely impairs the immune system, leading to life-threatening infections. The bacterium Mycoplasma genitalium, though lesser known, is linked to conditions such as urethritis and pelvic inflammatory disease. Syphilis, a bacterial infection, progresses through stages, initially causing sores and skin rashes and, without treatment, severe damage to internal organs. Lastly, Trichomoniasis, caused by the Trichomonas vaginalis protozoan, is characterized by itching and discharge but is typically curable with antibiotics.

End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases

Sexually transmitted disease (STD) diagnostics encompass various healthcare and research settings, each playing an important role in the detection, analysis, and management of STDs. Clinics are often the frontline in STD diagnostics, providing accessible testing services directly to the public. Diagnostic laboratories specialize in the analysis of samples, utilizing advanced technologies to ensure accurate results. Hospitals offer comprehensive care, including STD diagnostics, especially in more severe or complicated cases that require in-patient care. Public health agencies are integral to the surveillance, prevention, and control of STDs, using diagnostic data to inform public health strategies and interventions. Moreover, research institutions are key in developing new diagnostic methods and understanding the epidemiology of STDs, contributing to the scientific foundation necessary for advancing public health measures and clinical practices.

Regional Insights

In the Americas, the growing prevalence of sexually transmitted diseases (STDs), coupled with increased health awareness and healthcare spending, propels demand for diagnostic solutions. Advanced healthcare infrastructure and the high adoption of cutting-edge diagnostic technologies contribute to sophisticated consumer expectations. Recent initiatives include significant investments in public health programs to enhance STD diagnostics among underprivileged populations. At the same time, the EMEA shows a proactive approach towards STD diagnostics, supported by governmental and non-governmental initiatives that facilitate research, development, and distribution of innovative diagnostics solutions. The emphasis is on cost-effectiveness and comprehensive coverage, aiming for urban and rural accessibility. In recent years, the region has witnessed gradual progress with initiatives aimed at education, awareness, and breaking the stigma around STDs, slowly increasing the demand for diagnostic services. Moreover, the Asia-Pacific region is keen on growth in the market for STD diagnostics, driven by increasing awareness, rising prevalence of STDs, and government initiatives aimed at curbing these infections. With a diverse population and varying healthcare infrastructure across countries, including China, India, Japan, and Australia, the market dynamics are characterized by a mix of advanced technological adoption and growing demand for cost-effective diagnostic solutions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sexually Transmitted Disease Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sexually Transmitted Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sexually Transmitted Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech Gmbh, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd, Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., OraSure Technologies, Inc., Qiagen Inc, Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Sexually Transmitted Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Disease Type
  • Bacterial Vaginosis
  • Candidal Vaginitis
  • Chlamydia Trachomatis/ Neisseria Gonorrhoeae
  • Genital Warts
  • Hepatitis B
  • HIV/AIDS
  • Mycoplasma Genitalium
  • Syphilis
  • Trichomoniasis

• Diagnostic methods
  • Antigen Detection
  • Molecular Diagnostics
  • Serologic Testing

• Device Type
  • Laboratory Devices
    • Absorbance Microplate Reader
    • Differential Light Scattering Machines
    • Flow Cytometers
    • Lateral Flow Readers
    • Thermal Cyclers - PCR

• Point of Care Devices
  • Phone Chips (Microfluidics + ICT)
  • Rapid Diagnostic Kits
• End-Users
  • Clinics
  • Diagnostic Laboratories
  • Hospitals
  • Public Health Agencies
  • Research Institutions

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Sexually Transmitted Disease Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sexually Transmitted Disease Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Sexually Transmitted Disease Diagnostics Market?

4. What is the market share of the leading vendors in the Sexually Transmitted Disease Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Sexually Transmitted Disease Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
    • 5.1.1.2. Increasing implementation of worldwide screening to reduce the stigma associated with STD
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of adequate awareness and education about STDs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased funding and public health campaigns for STD awareness and prevention
    • 5.1.3.2. Innovations in next-generation sequencing and CRISPR-based diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations for drug approvals and complications arising from untreated infections
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs
  • 5.2.2. End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Sexually Transmitted Disease Diagnostics Market, by Disease Type

• 6.1. Introduction
• 6.2. Bacterial Vaginosis
• 6.3. Candidal Vaginitis
• 6.4. Chlamydia Trachomatis/ Neisseria Gonorrhoeae
• 6.5. Genital Warts
• 6.6. Hepatitis B
• 6.7. HIV/AIDS
• 6.8. Mycoplasma Genitalium
• 6.9. Syphilis
• 6.10. Trichomoniasis

7. Sexually Transmitted Disease Diagnostics Market, by Diagnostic methods

• 7.1. Introduction
• 7.2. Antigen Detection
• 7.3. Molecular Diagnostics
• 7.4. Serologic Testing

8. Sexually Transmitted Disease Diagnostics Market, by Device Type

• 8.1. Introduction
• 8.2. Laboratory Devices
• 8.3. Point of Care Devices

9. Sexually Transmitted Disease Diagnostics Market, by End-Users

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals
• 9.5. Public Health Agencies
• 9.6. Research Institutions

10. Americas Sexually Transmitted Disease Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Sexually Transmitted Disease Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Sexually Transmitted Disease Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. British startup launches tampon that offers STI screening
  • 13.3.2. BioPerfectus Launches New PCR Kits for Sexually Transmitted Diseases Diagnostic Solution
  • 13.3.3. Mylab Launches rapid tests for sexually transmitted diseases
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio